+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

How Do Patients Respond to Genetic Testing for Age-related Macular Degeneration?



How Do Patients Respond to Genetic Testing for Age-related Macular Degeneration?



Optometry and Vision Science 95(3): 166-170



The American Academy of Ophthalmology currently recommends against routine genetic testing for complex diseases such as age-related macular degeneration (AMD). The results of this study demonstrate that patients are very interested in predictive genetic testing for AMD, find the information useful, and make behavioral changes as a result of the information. The goal of this project was to conduct a pilot AMD genomic medicine study. Eligible patients were aged 50 to 65 years with no personal history of AMD. DNA samples were genotyped for five single-nucleotide polymorphisms (SNPs) in the CFH gene, one SNP in the ARMS-2 gene, one SNP in the C3 gene, and one SNP in the mitochondrial ND2 gene. A risk score was calculated utilizing a model based on odds ratios, lifetime risk of advanced AMD and known population prevalence of genotype, haplotype, and smoking risk. The study optometrist provided the patient's risk score and counseling for personal protective behaviors. Telephone interviews were conducted 1 to 3 months after the counseling visit. One hundred one subjects (85%) participated in the genetic testing; 78 (77.2%) were female. Follow-up interviews were conducted with 94 participants (93.1%). More than half (n = 48) of the participants said that they were motivated to participate in the study because they had a family member with AMD or another eye or genetic disorder. Despite low risk levels, many participants reported making changes as a result of the genetic testing. Twenty-seven people reported making specific changes, including wearing sunglasses and brimmed hat and taking vitamin supplements. Another 16 people said that they were already doing the recommended activities, including wearing glasses, quitting smoking, and/or taking vitamins. Interest in genetic testing for future risk of AMD was high in this population and resulted in support to continue current health behaviors or incentive to improve behaviors related to eye health.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065202082

Download citation: RISBibTeXText

PMID: 29424826

DOI: 10.1097/opx.0000000000001188


Related references

Genetic testing for age-related macular degeneration: not indicated now. JAMA Ophthalmology 133(5): 598-600, 2015

Genetic testing for age-related macular degeneration. Ophthalmology 113(4): 509-510, 2006

Population differences in genetic risk for age-related macular degeneration and implications for genetic testing. Archives of Ophthalmology 130(1): 116-117, 2012

Predictive value of multiple genetic testing for age-related macular degeneration. Archives of Ophthalmology 125(9): 1270-1271, 2007

Development of typical age-related macular degeneration and polypoidal choroidal vasculopathy in fellow eyes of Japanese patients with exudative age-related macular degeneration. American Journal of Ophthalmology 146(1): 96-101, 2008

Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration. Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study. Graefe's Archive for Clinical and Experimental Ophthalmology 241(12): 968-974, 2003

Mini-cognitive testing in patients with age-related macular degeneration. Retina 34(5): 868-873, 2014

Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761). Ophthalmology 124(3): E31-E32, 2017

Genetic analysis of complement factor H related 5, CFHR5, in patients with age-related macular degeneration. Molecular Vision 15: 731-736, 2009

Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. American Journal of Ophthalmology 136(6): 1049-1061, 2003

Repeatability of contrast sensitivity testing in patients with age-related macular degeneration, glaucoma, and cataract. Arquivos Brasileiros de Oftalmologia 79(5): 323-327, 2016

Genetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?. Ophthalmology 122(1): 212-215, 2015

Clinical and Genetic Characteristics of Japanese Patients with Age-Related Macular Degeneration and Pseudodrusen. Ophthalmology 123(10): 2205-2212, 2016

Age-related macular degeneration in grandparents of patients with Stargardt disease: genetic study. American Journal of Ophthalmology 128(2): 173-178, 1999

Macular function in eyes with early age-related macular degeneration with or without contralateral late age-related macular degeneration. Retina 27(7): 879-890, 2007